North America Liquid Biopsy Market Size & Outlook
North America liquid biopsy market, 2018-2030 (US$M)
Related Markets
North America liquid biopsy market highlights
- The North America liquid biopsy market generated a revenue of USD 5,427.0 million in 2023.
- The market is expected to grow at a CAGR of 11.5% from 2024 to 2030.
- In terms of segment, blood sample was the largest revenue generating type in 2023.
- Blood Sample is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 5,427.0 million |
| Market revenue in 2030 | USD 11,638.3 million |
| Growth rate | 11.5% (CAGR from 2023 to 2030) |
| Largest segment | Blood sample |
| Fastest growing segment | Blood Sample |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, North America region accounted for 50.8% of the global liquid biopsy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,678.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample was the largest segment with a revenue share of 73.2% in 2023. Horizon Databook has segmented the North America liquid biopsy market based on blood sample covering the revenue growth of each sub-segment from 2018 to 2030.
North America leads the global liquid biopsy market in terms of revenue generation, owing to high cancer prevalence, rapid technological advancements, and growing government initiatives.
The North America market is led by the U.S. owing to greater investments and presence of several biotechnology companies developing advanced tests. Various organizations, such as American Society of Clinical Oncology, are engaged in supporting the implementation of liquid biopsy, which is likely to boost revenue in this market.
A rise in the number of approvals of new diagnostic tests is anticipated to fuel the market growth further in the near future. For instance, in July 2022, Nanostics, Inc. announced the launch of a clinical investigation for bladder cancer to identify the most effective indicators of the disease for early detection.
Reasons to subscribe to North America liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America liquid biopsy market , including forecasts for subscribers. This continent databook contains high-level insights into North America liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America liquid biopsy market size, by country, 2018-2030 (US$M)
North America Liquid Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
